Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Operating Leases (2021 - 2026)

Aura Biosciences filings provide 6 years of Operating Leases readings, the most recent being $13.7 million for Q1 2026.

  • Quarterly Operating Leases fell 10.14% to $13.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Mar 2026, down 10.14% year-over-year, with the annual reading at $14.1 million for FY2025, 9.51% down from the prior year.
  • Operating Leases hit $13.7 million in Q1 2026 for Aura Biosciences, down from $14.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $18.1 million in Q3 2022 and bottomed at $51000.0 in Q2 2022.
  • Average Operating Leases over 5 years is $14.3 million, with a median of $16.0 million recorded in 2024.
  • The largest annual shift saw Operating Leases skyrocketed 34031.37% in 2023 before it decreased 10.14% in 2026.
  • Aura Biosciences' Operating Leases stood at $17.9 million in 2022, then decreased by 5.73% to $16.9 million in 2023, then decreased by 7.41% to $15.6 million in 2024, then dropped by 9.51% to $14.1 million in 2025, then dropped by 2.9% to $13.7 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Operating Leases are $13.7 million (Q1 2026), $14.1 million (Q4 2025), and $14.5 million (Q3 2025).